Tevogen Bio Holdings Inc. (TVGN): Nasdaq/NYSE listing notice — Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026

Tevogen Bio Holdings Inc.

Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.
Common stock closing bid below $1.00 for 30 consecutive business days; no immediate impact on listing.
Has 180 days (until March 23, 2026) to regain compliance by closing at $1.00+ for at least 10 consecutive days.
If not cured, may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
Company will monitor bid price and evaluate options; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

September 23, 2025, Tevogen Bio Holdings Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets Nasdaq’s $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”) for continued listing on Nasdaq based on the closing bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the previous 30 consecutive business days. The notification received has no immediate eff

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-015784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.